Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 5/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30046905 | 1.00 | PBRM1 (0.44) | PBRM1BRD4CREBBPAKR1B1MAPKAPK2 | |
| SCHEMBL10197537 | 1.00 | PBRM1 (0.44) | PBRM1BRD4CREBBPAKR1B1MAPKAPK2 | |
| SCHEMBL16823857 | 0.86 | PBRM1 (0.47) | PBRM1BRD4CREBBPAKR1B1MAPKAPK2 | |
| SCHEMBL16123162 | 0.86 | PBRM1 (0.47) | PBRM1BRD4CREBBPAKR1B1MAPKAPK2 | |
| SCHEMBL22791448 | 0.81 | CREBBP (0.46) | BRD4CREBBPAKR1B1MAPKAPK2MAPT | |
| SCHEMBL7345041 | 0.81 | CREBBP (0.46) | BRD4CREBBPAKR1B1MAPKAPK2MAPT | |
| SCHEMBL23920083 | 0.79 | AKR1B1 (0.39) | BRD4CREBBPAKR1B1AHRHTR2A | |
| SCHEMBL5245933 | 0.79 | BRD4 (0.59) | BRD4CREBBP | |
| SCHEMBL22955689 | 0.79 | AKR1B1 (0.39) | BRD4CREBBPAKR1B1AHRHTR2A | |
| SCHEMBL30991547 | 0.79 | AKR1B1 (0.39) | BRD4CREBBPAKR1B1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300129-B | Heterocyclic compounds as BCR-ABL inhibitors | 苏州亚盛药业有限公司 | 2021-09-14 | — | — | CN | disclosed |
| WO-2021018194-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-02-04 | — | — | WO | disclosed |
| CN-112300129-A | Heterocyclic compounds as BCR-ABL inhibitors | 苏州亚盛药业有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-8637507-B2 | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637507-B2 | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010107768-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010107765-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | PBRM1 4071/4885BRD4 157/4885CREBBP 805/4885 |
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | PBRM1 4375/4885BRD4 181/4885CREBBP 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.